5-氰基吲哚-2-硼酸 | 871329-64-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-氰基吲哚-2-硼酸
• 中文别名: 5-氰基-1H-吲哚-2-硼酸
• 英文名称: 5-cyanoindole-2-boronic acid
• 英文别名: (5-cyano-1H-indol-2-yl)boronic acid
• CAS: 871329-64-5
• 化学式: C₉H₇BN₂O₂
• mdl: MFCD06798223
• 分子量: 185.978
• InChiKey: UALSJXICMYXRMN-UHFFFAOYSA-N

物化性质

• 熔点：
  220-226℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80
• 氢给体数：
  3
• 氢受体数：
  3

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Cyanoindole-2-boronic acid
Synonyms: 5-Cyano-1H-indol-2-ylboronic acid; 5-Cyano-2-indoleboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Cyanoindole-2-boronic acid
CAS number: 871329-64-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H7BN2O2
Molecular weight: 186.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氰基吲哚-2-硼酸 在 四(三苯基膦)钯 氨 、 氢气 、 potassium carbonate 、 lithium iodide 作用下， 以 喹啉 、 甲醇 、 乙二醇二甲醚 、 水 、 甲苯 为溶剂， 50.0~200.0 ℃ 、413.7 kPa 条件下， 反应 16.17h， 生成 4-[5-(aminomethyl)-1H-indol-2-yl]-6-(4-methylphenyl)-5-pyrimidinol
  参考文献：
  名称：

  [EN] 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS
  [FR] DÉRIVÉS DE PYRIMIDINE 4,5,6-TRISUBSTITUÉE COMME INHIBITEURS DU FACTEUR IXA

  摘要：

  本发明涉及公式（I）的新颖杂环化合物：（化学式应按照纸质摘要中的形式插入此处）如本文所披露的公式（I），或其药学上可接受的盐、溶剂化合物、酯、前药或立体异构体。还披露了包括所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓栓塞性疾病的方法。

  公开号：

  WO2011017296A1
• 作为产物：
  描述：

  1-BOC-5-氰基吲哚 在 硼酸三异丙酯 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 环己烷 为溶剂， 反应 2.33h， 生成 5-氰基吲哚-2-硼酸 、 1-Boc-5-氰基吲哚-2-硼酸
  参考文献：
  名称：

  Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors

  摘要：

  该发明涉及公式（I）的化合物：其中R1代表吡唑基或吲唑基，R2和R3特别代表H、卤素、羟基、硝基、氰基、R4、—OR4、—COR4、—OC(═O)R4、—C(═O)OR4、—C(═O)OH、—N(R5)C(═O)R4、—N(R5)C(═O)OR4、—S(O)nR4、—S(O)nOR4、—N(R5)SO2R4、—NY1Y2、—C(═O)NY1Y2、—N(R5)C(═O)NY1Y2、—S(O)nNY1Y2和—OC(═O)NY1Y2，其中R4特别代表烷基、烯基、环烷基、芳基、杂芳基和杂环烷基，R5特别代表H、烷基、烯基、环烷基、杂环烷基、芳基和杂芳基，Y1和Y2特别代表H、烷基、烯基、环烷基、杂环烷基、芳基、芳基羧基、杂芳基和杂芳基羧基，可以选择地被取代，或者Y1和Y2与N形成氨基环，n代表0至2，所有这些基团都可以选择地被取代，这些产品以所有异构体形式和盐的形式作为药物产品，特别作为KDR抑制剂。

  公开号：

  US20040242559A1

文献信息

• [EN] 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE 4,5,6-TRISUBSTITUÉE COMME INHIBITEURS DU FACTEUR IXA
  申请人：SCHERING CORP

  公开号：WO2011017296A1

  公开（公告）日：2011-02-10

  The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

  本发明涉及公式（I）的新颖杂环化合物：（化学式应按照纸质摘要中的形式插入此处）如本文所披露的公式（I），或其药学上可接受的盐、溶剂化合物、酯、前药或立体异构体。还披露了包括所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓栓塞性疾病的方法。
• Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
  申请人：Aventis Pharma S.A.

  公开号：US20040242559A1

  公开（公告）日：2004-12-02

  The invention relates to compounds of formula (I): 1 in which R1 represents pyrazolyl or indazolyl, R2 and R3 especially represent H, halogen, hydroxyl, nitro, cyano, R4, —OR4, —COR4, —OC(═O)R4, —C(═O)OR4, —C(═O)OH, —N(R5)C(═O)R4, —N(R5)C(═O)OR4, —S(O)nR4, —S(O)nOR4, —N(R5)SO2R4, —NY1Y2, —C(═O)NY1Y2, —N(R5)C(═O)NY1Y2, —S(O)nNY1Y2 and —OC(═O)NY1Y2, R4 especially represents alkyl, alkenyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl, R5 especially represents H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, Y1 and Y2 especially represent H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylcarboxyl, heteroaryl and heteroarylcarboxy, which are optionally substituted, or Y1 and Y2 form with N an amino ring, n represents 0 to 2, all these radicals being optionally substituted, these products being in all the isomeric forms and the salts, as medicinal products, especially as KDR inhibitors.

  该发明涉及公式（I）的化合物：其中R1代表吡唑基或吲唑基，R2和R3特别代表H、卤素、羟基、硝基、氰基、R4、—OR4、—COR4、—OC(═O)R4、—C(═O)OR4、—C(═O)OH、—N(R5)C(═O)R4、—N(R5)C(═O)OR4、—S(O)nR4、—S(O)nOR4、—N(R5)SO2R4、—NY1Y2、—C(═O)NY1Y2、—N(R5)C(═O)NY1Y2、—S(O)nNY1Y2和—OC(═O)NY1Y2，其中R4特别代表烷基、烯基、环烷基、芳基、杂芳基和杂环烷基，R5特别代表H、烷基、烯基、环烷基、杂环烷基、芳基和杂芳基，Y1和Y2特别代表H、烷基、烯基、环烷基、杂环烷基、芳基、芳基羧基、杂芳基和杂芳基羧基，可以选择地被取代，或者Y1和Y2与N形成氨基环，n代表0至2，所有这些基团都可以选择地被取代，这些产品以所有异构体形式和盐的形式作为药物产品，特别作为KDR抑制剂。